Home » Forest, Almirall Announce Submission of New Drug Application for Aclidinium Bromide
Forest, Almirall Announce Submission of New Drug Application for Aclidinium Bromide
Forest Laboratories and Almirall, S.A. announced they have recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for aclidinium bromide, a long-acting inhaled antimuscarinic agent developed for the treatment of Chronic Obstructive Pulmonary Disease.
MarketWatch
MarketWatch
Upcoming Events
-
07May
-
14May
-
30May